ATEC Collapses 38% as Q3 Miss Erases CEO's Confidence Trade

Alphatec Holdings just delivered one of the sharpest single-session drops in its recent history, as a Q3 earnings miss obliterated the bullish setup that had been building into the print.

The damage is stark. The stock closed at $7.04 on October 30, down 38% on the day and 37% on the week. That wipes out not only the 29% rally that had followed CEO Patrick Miles's $1.01 million open-market purchase at $8.81 in September, but pushes the stock well below his entry price. The CEO's discretionary buy, flagged in the pre-earnings note here as a concrete anchor for the bull case, has turned into an underwater position. Q3 revenue missed consensus by $5 million, and the EPS loss of $0.22 was far worse than the $0.02 loss the Street had penciled in. Full-year revenue guidance was cut to $882 million from $890 million, with EOS imaging again the primary culprit, its sales down roughly 18% year over year.

Options positioning had been flashing a warning. The put/call ratio closed Thursday at 0.45, more than 3.5 standard deviations above its 20-day mean of 0.31. That was the most defensive reading in at least a year, well above the 52-week average range, and it now looks like prescient hedging rather than noise. Short interest, meanwhile, told a slightly different story: bears had actually been trimming, with short positions falling nearly 7% over the past week to 9.3% of the free float, around 13.8 million shares. Borrow remains easy, with availability at 393% of outstanding short interest and a cost to borrow below 0.5%. The lending market is not tight. That combination, shorts cutting and puts spiking, now reads as options traders correctly anticipating what the short sellers were beginning to doubt.

The Street's reaction was swift and uniform. JP Morgan, TD Cowen, Wells Fargo, and Needham all cut price targets on October 30, though every one of them maintained positive ratings. JP Morgan kept Overweight and trimmed to $15. TD Cowen held Buy and cut to $10. Wells Fargo and Needham both came in at $12 with Overweight and Buy respectively. The consensus mean target now sits at roughly $15.57, which is more than double the current price. That gap is not a buying signal by itself; it reflects a Street that has not yet reset its models fully and may take several weeks to converge. The bull case, as articulated before the print, rested on spine surgery momentum: 17% revenue growth year over year, case volume up 21%, and new surgeon users up 23%. That story is intact on the surgical side. The bear case has always been EOS execution, and EOS delivered another miss.

The institutional register adds context. BlackRock added 1.24 million shares as of September 30, lifting its stake to 7.3% of shares. Braidwell LP built a new position of 6.5 million shares in the June quarter. Patrick Miles himself holds 5 million shares, now worth roughly $35 million at the post-earnings price, down from over $57 million at the pre-print high. The activist register carries two 13D filers, Jennifer Pritzker at 8.9% (last disclosed December 2025) and L-5 Healthcare Partners at just under 5% (last disclosed April 2025). Both stakes are event-driven disclosures around the 5% threshold and should be read as "as last disclosed"; either holder could have changed position since. Nonetheless, the presence of two Schedule 13D filers alongside a CEO who put $1 million of personal capital into the stock just six weeks ago gives the ownership picture a different character than a straightforward short thesis would imply.

Wikipedia attention for ATEC spiked to a z-score of 4.76 relative to its own 90-day history, measured as of October 19, reflecting the retail attention that had been building ahead of the print. That kind of attention spike around earnings typically dissipates quickly after the event, one way or another.

The short score eased modestly to 60.3 from a recent peak above 63, but remains elevated. The question now is whether the bears who trimmed ahead of earnings begin rebuilding positions at $7, or whether the surgical growth story, still real on the numbers, attracts buyers who treat the EOS drag as a known and finite problem. What to watch: whether short interest rebuilds materially in the next two weeks, and whether any of the 13D holders file an amendment that clarifies their current stance.